Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Controlled hypernatremia].

L Petit1, F Masson, V Cottenceau

  • 1Unité de Réanimation Chirurgicale et Traumatologique, Département d'Anesthésie-Réanimation, CHU Pellegrin, 1, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

Annales Francaises D'Anesthesie Et De Reanimation
|July 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Emergency room visits for asthma and the reported outcomes: The PASS survey by the CRISALIS network].

Revue des maladies respiratoires·2025
Same author

Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.

ESMO open·2024
Same author

Detection of fungi in the airways of horses according to the sample site: a methodological study.

Veterinary research communications·2023
Same author

Upconversion from fluorophosphate glasses prepared with NaYF<sub>4</sub>:Er<sup>3+</sup>,Yb<sup>3+</sup> nanocrystals.

RSC advances·2022
Same author

Nucleation and growth behavior of Er<sup>3+</sup> doped oxyfluorophosphate glasses.

RSC advances·2022
Same author

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same journal

Annales francaises d'anesthesie et de reanimation·2020
Same journal

[Multimodal approach to enhance filter lifespan: are all actions equal?].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Disparity of French Emergency medical services equipment: disparity of funding allocation or of management quality?].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Eligibility to a Maastricht III - type organ donation according to the protocol proposed by the French organ procurement organization (Agence de la biomedicine) among patients in a medico surgical intensive care unit].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Enhanced recovery after elective colorectal surgery: reply].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Aorto-right atrial fistula as complication of aortic dissection].

Annales francaises d'anesthesie et de reanimation·2014
See all related articles

Hypertonic saline (HS) can reduce brain swelling and intracranial pressure in brain injury patients. Careful monitoring is crucial due to potential adverse effects.

Area of Science:

  • Neuroscience
  • Neurosurgery
  • Critical Care Medicine

Context:

  • Hypernatremia impacts the brain via osmotic gradients across the blood-brain barrier.
  • Cellular dehydration and shrinkage occur due to water shifts from intracellular to vascular spaces.
  • Osmoregulation mechanisms attempt to restore normal cell volume.

Purpose:

  • To review the effects of hypertonic saline (HS) in managing intracranial hypertension.
  • To evaluate the efficacy and limitations of HS in reducing intracranial pressure (ICP).

Summary:

  • Hypertonic saline (HS) administration can decrease cerebral volume and intracranial pressure (ICP), even during hemorrhagic shock.
  • Early clinical studies showed HS as a viable alternative to mannitol for acute and refractory intracranial hypertension.

Related Experiment Videos

  • Continuous HS infusions demonstrated potential for ICP control, though evidence is mainly from non-randomized pediatric studies.

    • Impact:

    • HS may be a reasonable option for refractory intracranial hypertension under strict natremia and adverse effect monitoring.
    • Further research, including randomized controlled trials, is needed to confirm HS efficacy and safety.
    • Understanding HS's osmotic effects is crucial for neurocritical care management.